For the quarter ending 2025-09-30, HROW made $71,638,000 in revenue. $1,020,000 in net income. Net profit margin of 1.42%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenues | 71,638,000 | 63,742,000 | 47,831,000 | 50,709,000 |
| Cost of sales | 17,712,000 | 16,230,000 | 15,524,000 | 12,344,000 |
| Gross profit | 53,926,000 | 47,512,000 | 32,307,000 | 38,365,000 |
| Selling, general and administrative | 35,856,000 | 33,235,000 | 40,513,000 | 31,801,000 |
| Research and development | 3,323,000 | 2,868,000 | 3,026,000 | 3,452,000 |
| Impairment of long-lived assets | - | - | - | 63,250 |
| Total operating expenses | 39,179,000 | 36,103,000 | 43,539,000 | 35,379,500 |
| Income (loss) from operations | 14,747,000 | 11,409,000 | -11,232,000 | 2,985,500 |
| Interest expense, net | 6,038,000 | 6,408,000 | 6,548,000 | 5,895,000 |
| Loss on extinguishment of debt | -7,750,000 | - | - | - |
| Investment loss from eton pharmaceuticals | - | 0 | - | -416,000 |
| Other income, net | 61,000 | -6,000 | - | -117,500 |
| Total other expense, net | -13,727,000 | -6,414,000 | -6,548,000 | -6,636,500 |
| Income (loss) before income taxes | 1,020,000 | 4,995,000 | - | -3,651,000 |
| Income tax expense | - | 0 | - | -257,000 |
| Net income (loss) | 1,020,000 | 4,995,000 | -17,780,000 | -3,394,000 |
| Basic net income (loss) per share of common stock | 0.03 | 0.14 | -0.5 | -0.095 |
| Diluted net income (loss) per share of common stock | 0.03 | 0.13 | -0.5 | -0.095 |
| Weighted average number of shares of common stock outstanding, basic | 37,145,440 | 36,790,306 | 35,826,452 | -17,835,231.5 |
| Weighted average number of shares of common stock outstanding, diluted | 38,875,005 | 38,853,855 | 35,826,452 | -17,835,231.5 |
HARROW, INC. (HROW)
HARROW, INC. (HROW)